Ventripoint Diagnostics (TSXV: VPT) is progressing with its joint venture partner in China. This morning the firm revealed that its partner, Yutian Medical Shanghai, has begun actively working with regulatory bodies to have its device certified for use with COVID patients.
The certification for this application follows Chinese guidelines being modified for the treatment and diagnosis of COVID-10 patients in the country, which now require monitoring of right-ventricular function by non-invasive techniques. Given the suitability of the QMS device (the rebranded name for VMS in the region) for such an application, the joint venture has begun the certification process.
To date, the venture has been successful in placing the devices in intensive care units, with further demand anticipated to meet potential future needs as the hospital deals with COVID. The application of the devices for this purpose as a result substantially expands the potential market for the device, beyond just that of cardiovascular disease.
Sponsored · Antimony Resources
Ventripoint Diagnostics last traded at $0.53 on the TSX Venture.
FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
